Legal & General Group Plc Buys 6,257 Shares of IQVIA Holdings Inc. $IQV

Legal & General Group Plc boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,132,304 shares of the medical research company’s stock after acquiring an additional 6,257 shares during the period. Legal & General Group Plc owned approximately 0.66% of IQVIA worth $215,070,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Pinkerton Wealth LLC increased its position in shares of IQVIA by 27.8% during the third quarter. Pinkerton Wealth LLC now owns 21,443 shares of the medical research company’s stock valued at $4,073,000 after purchasing an additional 4,659 shares during the period. Banque Cantonale Vaudoise lifted its position in IQVIA by 51.2% in the third quarter. Banque Cantonale Vaudoise now owns 10,192 shares of the medical research company’s stock worth $1,936,000 after purchasing an additional 3,451 shares during the period. WINTON GROUP Ltd acquired a new stake in IQVIA during the third quarter worth $3,383,000. Russell Investments Group Ltd. increased its holdings in IQVIA by 34.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 82,011 shares of the medical research company’s stock valued at $15,367,000 after buying an additional 20,901 shares during the period. Finally, Private Advisor Group LLC raised its stake in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $162.45 on Friday. The stock has a 50-day simple moving average of $202.79 and a 200 day simple moving average of $206.83. The stock has a market capitalization of $27.57 billion, a price-to-earnings ratio of 20.67, a P/E/G ratio of 1.66 and a beta of 1.39. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the prior year, the firm earned $3.12 EPS. The company’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IQV. Jefferies Financial Group decreased their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Morgan Stanley set a $240.00 price objective on IQVIA in a research note on Wednesday, February 11th. Finally, BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.